1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs
  4. >>Emerging Company Profiles

Iksuda Aims For Best-In-Class Cancer ADCs With Toolbox Approach To Technology

 
• By Ayisha Sharma

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.  

Emerging Company Profile: Iksuda Therapeutics
PermaLink Can Design ADCs That Are Insusceptible To De-Conjugation • Source: Shutterstock
Key Takeaways:

  • Iksuda’s PermaLink technology can design ADCs insusceptible to drug de-conjugation.

Iksuda Therapeutics is on mission to design and develop more securely conjugated and efficacious antibody-drug conjugates (ADCs) for the treatment of cancers and is taking a liberated approach to using technology.

The UK firm’s story goes back to 2007 when investor IP Group founded a company called Glythera with two platforms...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Emerging Company Profiles

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Immusoft Goes For Cell Therapy Plan ‘B’

 
• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

 
• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

 
• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

More from Start-Ups & SMEs

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.